<DOC>
	<DOCNO>NCT00992797</DOCNO>
	<brief_summary>The aim 6 month study evaluate metabolic effect 400.000-600.000 IU vitamin D supplementation subject type 2 diabetes hypovitaminosis D. The main hypothesis subject low level 25-OH-vitamin D benefit supplementation cholecalciferol sufficient dos optimize serum level .</brief_summary>
	<brief_title>Diabetes Intervention Trial With Vitamin D Subjects Nordic Sub-Indian Ethnicity</brief_title>
	<detailed_description>Accumulating evidence suggest hypovitaminosis D may associate development type 2 diabetes disturbance glucose insulin metabolism . There lack data randomize , controlled study sufficient duration use sufficient dos vitamin D ass importance vitamin D supplementation glucose metabolism type 2 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Avitaminosis</mesh_term>
	<mesh_term>Rickets</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Inclusion criterion : 1 . Moderate ( S25OHD 2550 nmol/l ) severe ( S25OHD &lt; 25 nmol/l ) vitamin D deficiency measure Visit 1 . 2 . Patients type 2 diabetes , include drug naïve subject , subject use oral antidiabetic medication subject insulin treatment . All medication must stable dos 4 week leadin period . 3 . HbA1c &lt; 11 % Visit 1 . 4 . Able communicate Norwegian . 5 . Men woman ≥ 18 year . 6 . Norwegian South Asian ethnicity . 7 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study . All WOCBP must negative serum urine pregnancy test enrollment , randomization , titration visit final study assessment . 8 . Antihypertensive medication , lipid lower drug , oral contraceptive , hormone replacement therapy , multivitamin supplement nutritional supplement allow subject adhere regimen study 1 . Subjects type 2 diabetes . 2 . SBP ≥ 160 DBP ≥ 95 Visit 1 . 3 . Significant renal disease chronic renal impairment , GFR &lt; 30 ml/min . 4 . Significant liver disease ASAT ALAT &gt; 3x UNL . 5 . Malignancy last five year . 6 . Hypercalcemia Visit 1 . 7 . A history kidney stone disease 8 . WOCBP unwilling unable use acceptable method avoid pregnancy . 9 . Pregnant breastfeed woman . 10 . Chronic inflammatory disease active phase 11 . Long term ( &gt; 2 week ) use corticosteroid last 3 month 12 . Mental condition ( psychiatric organic cerebral disease ) render subject unable understand nature , scope possible consequence study . 13 . Drug alcohol abuse . 14 . BMI &gt; 45 kg/m2 bariatric surgery ( &lt; 5 year ) . 15 . Anemia 16 . Cardiovascular disease ( myocardial infarction , unstable angina pectoris stroke ) last 6 month . 17 . Any medical condition judgment investigator would jeopardize subject 's safety evaluation study drug efficacy safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Insulin resistance</keyword>
	<keyword>Insulin secretory dysfunction</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Vascular stiffness</keyword>
</DOC>